Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1441 to 1455 of 8314 results

  1. Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)

    Evidence-based recommendations on fludarabine monotherapy for untreated chronic lymphocytic leukaemia in adults.

  2. Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)

    Evidence-based recommendations on carmustine implants (Gliadel) and temozolomide for treating newly diagnosed high-grade glioma in adults.

  3. Varenicline for smoking cessation (TA123)

    Evidence-based recommendations on varenicline (Champix) for adults who want to stop smoking.

  4. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

    Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults.

  5. Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

    Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.

  6. Bisphosphonates for treating osteoporosis (TA464)

    Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.

  7. Sorafenib for treating advanced hepatocellular carcinoma (TA474)

    Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.

  8. Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)

    Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel; Abraxane) for untreated metastatic pancreatic cancer in adults.

  9. Entecavir for the treatment of chronic hepatitis B (TA153)

    Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.

  10. Pemetrexed for the treatment of non-small-cell lung cancer (TA124)

    Evidence-based recommendations on pemetrexed for treating non-small-cell lung cancer in adults.

  11. Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)

    Evidence-based recommendations on natalizumab (Tysabri) for treating highly active relapsing–remitting multiple sclerosis in adults.

  12. Stapled haemorrhoidopexy for the treatment of haemorrhoids (TA128)

    Evidence-based recommendations on stapled haemorrhoidopexy for treating haemorrhoids in adults.

  13. Bortezomib monotherapy for relapsed multiple myeloma (TA129)

    Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults.

  14. Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) (TA703)

    NICE is unable to make a recommendation on ibrutinib (Imbruvica) with rituximab for untreated chronic lymphocytic leukaemia because Janssen did not provide an evidence submission.

    Sections for TA703

  15. Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477)

    Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.